{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-040767","form_type":"8-K","ticker":"PYXS","cik":"0001782223","company_name":"Pyxis Oncology, Inc.","filed_at":"2025-03-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.834425+00:00","generated_at":"2026-05-24T14:07:53.363490+00:00","sec_items":["2.02","5.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Pyxis Oncology reports FY2024 net loss $77.3M; MICVO 50% ORR in HNSCC; workforce cut 20%","bullets":["Full year 2024 net loss $77.3M ($1.32 per share) vs $73.8M ($1.85) in 2023; cash $128.4M into 2H26.","MICVO (formerly PYX-201) achieved 50% confirmed ORR by RECIST 1.1 in R/M HNSCC Phase 1; Fast Track designation received.","Initiated MICVO monotherapy expansion cohorts and a Phase 1/2 combo trial with Merck's KEYTRUDA; data expected 2H25/1H26.","Workforce reduced ~20% primarily in G&A and preclinical; CMO Ken Kobayashi steps down; CEO Lara Sullivan to also serve as CMO.","Suspended PYX-106 development; recorded $21M non-cash impairment on PYX-107 IPR&D intangible."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-040767","json":"https://secwatch.observer/filing/0000950170-25-040767.json","markdown":"https://secwatch.observer/filing/0000950170-25-040767.md","text":"https://secwatch.observer/filing/0000950170-25-040767.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1782223/000095017025040767/0000950170-25-040767-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1782223/000095017025040767/pyxs-20250318.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T14:07:53.363490+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"58c091a31a","claim":"Lara S. Sullivan changed role as Chief Medical Officer at Pyxis Oncology, Inc..","evidence_excerpt":"Lara S. Sullivan, M.D., President and Chief Executive Officer will assume the role of Chief Medical Officer along with her current role as President and Chief Executive Officer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1782223/000095017025040767/0000950170-25-040767-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"assumed"},{"label":"Role","value":"Chief Medical Officer"}],"fact_type":"executive_change"},{"claim_id":"92fb570fc3","claim":"Ken Kobayashi departed as Chief Medical Officer at Pyxis Oncology, Inc..","evidence_excerpt":"On March 18, 2025, the Company announced that Ken Kobayashi, M.D., F.A.C.P, is stepping down from his position as the Company's Chief Medical Officer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1782223/000095017025040767/0000950170-25-040767-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"stepping down"},{"label":"Role","value":"Chief Medical Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}